News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors
Photo taken from genengnews.com
Aug 6, 2024, 11:41

Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors

Norbert Kraut,Global Head of Cancer Research at Boehringer Ingelheim, shared on X:

“Out now in Nature Cancer Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim KRAS team.”

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Authors: Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A. Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A. Machado, Thomas Madensky, Ethan D. Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M. Molkentine, Philipp A. Jaeger, David H. Peng, Robyn L. Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P. Vellano, Mark Petronczki, Norbert Kraut, Timothy P. Heffernan, Joseph R. Marszalek, Mark Pearson, Irene C. Waizenegger and Marco H. Hofmann.

Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors

Source: Norbert Kraut/X

Alexey Sorokin Annette A. Machado Astrid Jeschko Boehringer Ingelheim cancer Christoph Albrecht Christopher A. Bristow Christopher P. Vellano Daniel Gerlach David H. Peng Donat Alpar Ethan D. Marszalek Francesca Trapani Gabriella Melo-Zainzinger Hengyu Lyu Heribert Arnhof Irene C. Waizenegger Jessica M. Molkentine Joseph R. Marszalek Kaja Kostyrko Karin Bosch KRASG12C Marco H. Hofmann Mark Pearson Mark Petronczki MD Anderson Cancer Center Melanie Hinkel Michael Gmachl Mikhila Mahendra Nature Cancer Ningping Feng Norbert Kraut Oliver Bergner OncoDaily Oncology Philipp A. Jaeger relapsed mutant tumors Robyn L. Schenk Sabine Jurado Sandra Strauss Scott Kopetz Simone Lieb Sisi Gao Thomas Madensky Tim Heffernan Timothy P. Heffernan Venu Thatikonda
Special Coverage
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe
Blog
Dec 21, 2024, 19:18
The Institute of Cancer Research's annual report for 2023-2024